期刊文献+

人核糖核酸酶抑制因子基因重组腺病毒载体的构建及鉴定 被引量:1

Construction and identification of human ribonuclease gene recombinant adenovirus
下载PDF
导出
摘要 目的构建含有人核糖核酸酶抑制因子(hRI)基因的重组腺病毒载体。方法以含有全长cDNA的pT7-RI为模板,PCR扩增hRI,经T载体克隆后,酶切亚克隆到穿梭质粒pAdTrack-CMV上,在BJ5183细菌内和pAdEasy-1同源重组。筛选阳性克隆,酶切、PCR及测序鉴定,线性化后脂质体法转染293细胞进行包装、扩增。通过观察绿色荧光蛋白(GFP)的表达及PCR扩增目的基因等方法鉴定重组的腺病毒。结果酶切鉴定及PCR结果证明hRI基因重组腺病毒载体构建成功,病毒滴度为1.5×1010pfu/ml。结论应用细菌内同源重组法成功构建了含hRI基因的重组腺病毒载体。 Objective To construct the recombinant adenovirus vector containing human RI for future gene therapy. Methods The RI fragment was amplified by PCR according to the pT7-RI, then the fragment was cloned to T vector and subeloned to pAdTrack-CMV. The linearized shuttle plasmid was homogenously reeombined with pAdEasy-1 in BJ5183. The candidate clone was further analyzed by restriction endonuelease digestion and PCR. Then the recombined adenovirus was transfected into 293 cells for packaging and amplifying. The titer and its infection rate were determined using the green fluorescent protein (GFP) expression in the shuttle plasmid. Results Restriction endonuclease and PCR analysis confirmed that the human RI gene was successfully inserted into the adenovirus vector. The titer of the recombinant adenovirus was 1.5 × 10^10pfu/ml. Conclusion The recombinant adenovirus containing human RI gene was successfully constructed by the method of homogenous recombination in bacteria.
出处 《中国微生态学杂志》 CAS CSCD 2008年第6期547-549,共3页 Chinese Journal of Microecology
关键词 人核糖核酸酶抑制因子 腺病毒载体 基因治疗 Human ribonuelease inhibitor Adenovirus vector Gene therapy
  • 相关文献

参考文献9

  • 1崔秀云.核糖核酸酶抑制因子的结构及其功能[J].生命的化学,1991,11(3):19-20. 被引量:8
  • 2CHEN J X,TIAN Y X, FU P F, et al. Anti-tumor effect of hematopoietic cells carrying the gene of ribonuclease inhibitor[ J]. Can Gene Ther, 2005,12 ( 3 ) : 268-275.
  • 3陈俊霞,田余祥,傅攀峰,夏俊,阎平,崔秀云.转染人核糖核酸酶抑制因子基因对B16黑色瘤细胞及肿瘤转移的影响(英文)[J].生物化学与生物物理进展,2004,31(6):523-531. 被引量:11
  • 4KRAVCHENCO I V, FURALEV V. Secretion of corticotrophin releasing factor and adrenocoticotropic hormone by T and B lymphocytes in response to cen stress factors [ J ]. Biochem Biophys Res Commun, 1994,204 ( 2 ) : 828 -834.
  • 5FOLKMAN J. Tumor angiogenesis[ J]. Adv Cancer Res, 1985,43 ( 1 ) : 175 -203.
  • 6DREVS J, LAUS C, MENDINGER M, et al. Antiangiogenesis : Current clinical data and future perspectives [ J ]. Onkologie, 2002,25 ( 6 ) : 520-527.
  • 7NIA T, HILDEGUND C J E. Adenoviruses as vaccine vectors[ J]. Mole Ther,2004,10 (4) :616-620.
  • 8BREYER B,JIANG W, CHENG H, et al. Adenoviral vector-mediated gene transfer for human gene therapy [ J]. Curr Gene Ther, 2001,1 (2) :149-162.
  • 9HE T C,ZHOU S,da COSTA L T,et al. A simplified system for generating recombinant adenoviruses [ J ]. PNAS USA, 1998,95 ( 5 ) : 2509- 2514.

二级参考文献20

  • 1[1]Sharpiro R.Cytoplasmic ribonuclease inhibitor.In:Abelson JN,Simon MI,eds.Methods in Enzymology.San Diego:Academic Press,2001.611~628
  • 2[2]Papageorgiou A C,Shapiro R,Acharya K R.Molecular recognition of human angiogenin by placental ribonuclease inhibitor.EMBO J,1997,16(17):5162~5177
  • 3[3]Chen C Z,Shapiro R.Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A.Proc Natl Acad Sci USA,1997,94(5):1761~1766
  • 4[4]Rybak S M,Sanovich E,Hollingshead M G,et al."Vasocrine"formation of tumor cell- lined vascular spaces:implications for rational design of antiangiogenic therapies.Cancer Res,2003,63(11):2812~2819
  • 5[5]Cuadros C,Dominguez A L,Frost G L,et al.Cooperative effect between immunotherapy and antiangiogenic therapy leads to effective tumor rejection in tolerant Her-2/neu mice.Cancer Res,2003,63(18):5895~5901
  • 6[6]Estrada R B,Malet G,Revert F,et al.Antitumor effect of B16melanoma cells genetically modified with the angiogensis inhibitor RNasin.Cancer Gene Ther,2001,8(4):278~284
  • 7[7]Schneider R,Schneider-Scherzer E,Thurnher M,et al.The primary structure of human ribonuclease/angiogenin inhibitor(RI)discloses a novel highly diversified protein superfamily with a common repetitive module.EMBO J,1988,7(13):4151~4156
  • 8[8]Hofsteenge J.Ribonuclease inhibitor.In:D' Alessio G,Riordan J F,eds.Ribonuclease:Structures and Functions.New York:Academic Press,1997.621~623
  • 9[9]Polakowski I J,Lewis M K,Muthukkaruppan V R,et al.A ribonuclease inhibitor expression anti-angiogenic properties and leads to reduced tumor growth in mice.Am J Pathol,1993,143(2):507~517
  • 10[12]Menna P L,Skilton G S,Leskow F C,et al.Inhibition of aggressiveness of metastatic mouse mammary carcinoma cells by the β2-chimaerin GAP domain.Cancer Res,2003,63(9):2284~2291

共引文献17

同被引文献5

  • 1栗印兰,李静敏.核糖核酸酶抑制因子的研究进展[J].医学综述,2007,13(5):335-337. 被引量:2
  • 2del Olmo MF, Bello O, Cudeiro J. Transcranial magnetic stimulation over dorsolateral prefrontal cortex in Parkinson' s disease [ J ]. Clin Neurophysiol, 2007, 118( 1 ) : 131 - 139.
  • 3Tony AK, Anna MV, Jan H, et al. High-level soluble production and characterization of porcine ribonucleae inhibitor[J]. Protein Expr Purif, 2001, 22(2): 174-179.
  • 4Helmich RC, Siebner HR, Bakker M, et al. Repetitive transcranial magnetic stimulation to improve mood and motor function in parkinson's disease[J]. J Neurol Sci, 2006, 248(1 -2) : 84 -96.
  • 5Vijitruth R, Liu M, Choi DY, et al. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease[J]. J Neuroinflammation, 2006, 3(1): 6.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部